Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines published by researchers at Institute of Protein Biochemistry
May 6th, 2008
Data detailed in 'The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses' have been presented. According to recent research published in the Journal of Immunology, "Delivery of tumor-associated Ag-derived peptides in a high immunogenic form represents one of the key issues for effective peptide-based cancer vaccine development. We report herein the ability of nonpathogenic filamentous bacteriophage fd virions to deliver HLA-A2-restricted MAGE-A10(254-262)-or MAGE-A3(271-279)-derived peptides and to elicit potent specific CTL responses in vitro and in vivo." "Interestingly,...
Source: Cancer Weekly (2008-05-06)
|
